I’m still mulling the numbers in your post, but I have to admit that the FDA’s doubletalk at Friday’s advisory panel for Embeda (#msg-33590952) is not a good harbinger.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”